Bambusa Therapeutics, Inc. Stock: price and insider trades · United States
2 insiders bought €47.1M of shares over the last 90 days, the latest by RA CAPITAL MANAGEMENT, L.P., filed 03 Nov 2026.
Cluster: 2 buyers in 30 daysBambusa Therapeutics, Inc.: what insiders have been doing
Bambusa Therapeutics, Inc. is a listed company. Filings by its managers are published through SEC (Form 4). 4 insiders have disclosed 11 filings since 4 November 2025.
No insider sold shares on the market over the period. Instead, the filings list 5 purchases totalling €47.1M, made by 2 insiders. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. On the buying side, the filings list 1 major shareholder and 1 senior executive among the declarants. RA Capital Management, L.P. filed the largest purchase, €33.4M, on 3 November 2026.
For context, the typical company on the same exchange (median of 3,179 companies) published 24 filings over the same period, against 11 filings here. The full history, which starts in 2026, counts 5 purchases against no sales.
In the case of 1 purchase, another manager of the company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster. The most recent open-market purchase was published on 3 November 2026, 6 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. For comparison, the SEC allows two business days to file a Form 4.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Who traded when
BuySaleThis score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 189,909 shares@ US$14.23Common StockSEC:0001231919-26-001533:0Canonical exit: 28 Jan 2027 (T+90)
- 263,911 shares@ US$14.92Common StockSEC:0001231919-26-001533:1Canonical exit: 28 Jan 2027 (T+90)
- 3,144,858 sharesCommon StockSEC:0001231919-26-001533:2
- 1,331,080 sharesCommon StockSEC:0001231919-26-001533:3
- 2,335,109 shares@ US$16.00Common StockSEC:0001231919-26-001533:4Canonical exit: 31 Jan 2027 (T+90)
- 164,891 shares@ US$16.00Common StockSEC:0001231919-26-001533:5Canonical exit: 31 Jan 2027 (T+90)
- 4,769,701 sharesCommon StockSEC:0001982614-26-000004:0
- 4,769,701 sharesCommon StockSEC:0002162499-26-000004:0
- 16,358 sharesCommon StockSEC:0002160743-26-000013:0
- 147,238 sharesCommon StockSEC:0002160743-26-000013:1
- 375,000 shares@ US$16.00100.0% of flowCommon StockSEC:0002162499-26-000004:1Canonical exit: 31 Jan 2027 (T+90)
- 375,000 shares@ US$16.00100.0% of flowCommon StockSEC:0001982614-26-000004:1Canonical exit: 31 Jan 2027 (T+90)
12 of 12 declarations
About Bambusa Therapeutics, Inc.
Bambusa Therapeutics, Inc. is a biotechnology company focused on developing innovative treatments. It is listed on the XNAS market.
